Equities Analysts Offer Predictions for LENZ Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Leerink Partnrs issued their Q1 2024 EPS estimates for shares of LENZ Therapeutics in a note issued to investors on Monday, April 15th. Leerink Partnrs analyst M. Goodman expects that the company will post earnings of ($0.51) per share for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

Other equities analysts have also issued reports about the stock. William Blair assumed coverage on shares of LENZ Therapeutics in a report on Monday. They issued an “outperform” rating for the company. Piper Sandler began coverage on LENZ Therapeutics in a research note on Wednesday, March 27th. They issued an “overweight” rating and a $28.00 price target for the company. Citigroup began coverage on LENZ Therapeutics in a report on Wednesday, April 10th. They issued a “buy” rating and a $34.00 price objective for the company. Finally, SVB Leerink assumed coverage on shares of LENZ Therapeutics in a research note on Monday. They set an “outperform” rating and a $32.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $31.33.

LENZ Therapeutics Stock Performance

Shares of NASDAQ LENZ opened at $17.49 on Wednesday. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82. The company has a market capitalization of $145.52 million, a PE ratio of -1.12 and a beta of 0.20.

Insider Transactions at LENZ Therapeutics

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. bought 998,009 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The stock was bought at an average cost of $15.03 per share, for a total transaction of $15,000,075.27. Following the completion of the transaction, the director now owns 3,319,339 shares of the company’s stock, valued at approximately $49,889,665.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 38.40% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.